Pharmacological Properties of the Central Antihypertensive Agent, Moxonidine

Cardiovascular Therapeutics

Volumn 30, Issue 4, 2012, Pages 199-208

  Edwards, Lincoln P ^a   Brown Bryan, Terry A ^b   Mclean, Lancelot ^c   Ernsberger, Paul ^d  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive agents; Dyslipidemia; I 1 imidazoline receptor; Insulin resistance; Metabolic Syndrome; Moxonidine, Sympathoinhibition

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; GUANABENZ; IMIDAZOLINE I2 RECEPTOR; MOXONIDINE; PLACEBO; RILMENIDINE;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; CELL TYPE; CONGESTIVE HEART FAILURE; DRUG BINDING; DRUG SAFETY; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; METABOLIC SYNDROME X; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; HEART FAILURE; HUMANS; HYPERTENSION; IMIDAZOLES; INSULIN RESISTANCE; METABOLIC SYNDROME X; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS; TREATMENT OUTCOME;

EID: 84863222421     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00268.x     Document Type: Review

References (122)

1. Nambi V, Hoogwerf BJ, Sprecher DL. A truly deadly quartet: Obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. Cleve Clin J Med 2002;69:985-989.
2. Friedman JE, Ishizuka T, Liu S, Farrell CJ, Koletsky RJ, Bedol D, Ernsberger P. Anti-hyperglycemic activity of moxonidine: Metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press 1998;3:32-39.
3. De Luca N, Izzo R, Fontana D, Iovino G, Argenziano L, Vecchione C, Trimarco B. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens 2000;18:1515-1522.
4. Hansson L. Therapy of hypertension and metabolic syndrome: Today's standard and tomorrow's perspectives. Blood Press 1998;3:20-22.
5. Srivastava BK, Insulin MV. A Vasoactive Hormone. Int J Diab Dev Ctries 2002;22:111-114.
6. Egan BM. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep 2003;5:247-254.
7. Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. Rev Cardiovasc Med 2003;4(Suppl 6):S50-S57.
8. Hausberg M, Hoffman RP, Somers VK, Sinkey CA, Mark AL, Anderson EA. Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension 1997;29:700-705.
9. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-458.
10. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-4113.
11. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-912.
12. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 2006;48:219-224.
13. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989;298:1152-1157.
14. Swislocki AL, Hoffman BB, Sheu WH, Chen YD, Reaven GM. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989;86(1B): 14-18.
15. Andersson PE, Johansson J, Berne C, Lithell H. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens 1994;8:219-226.
16. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-381.
17. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002;40:329-334.
18. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Hirohashi K. Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr Med Chem Cardiovasc Hematol Agents 2005;3:61-67.
19. Dollery CT, Davies DS, Draffan GH, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 1976;19:11-17.
20. Davies DS, Wing AM, Reid JL, Neill DM, Tippett P, Dollery CT. Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther 1977;21:593-601.
21. Wing LM, Reid JL, Davies DS, Neill EA, Tippett P, Dollery CT. Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol 1977;12:463-469.
22. Head GA, Burke SL. Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit. J Hypertens 1998;16:503-517.
23. De Sarro GB, Ascioti C, Froio F, Libri V, Nistico G. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol 1987;90:675-685.
24. Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology 1992;76:948-952.
25. Correa-Sales C, Reid K, Maze M. Pertussis toxin-mediated ribosylation of G proteins blocks the hypnotic response to an alpha 2-agonist in the locus coeruleus of the rat. Pharmacol Biochem Behav 1992;43:723-727.
26. Nicholas AP, Pieribone V, Hokfelt T. Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: An in situ hybridization study. J Comp Neurol 1993;328:575-594.
27. Nicholas AP, Hokfelt T, Pieribone VA. The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci 1996;17:245-255.
28. Sun MK, Reis DJ. GABA-mediated inhibition of pacemaker neurons of rostral ventrolateral medulla by clonidine in vitro. Eur J Pharmacol 1995;276:291-296.
29. Scholtysik G, Lauener H, Eichenberger E, Burki H, Salzmann R, Muller-Schweinitzer E, Waite R. Pharmacological actions of the antihypertensive agent N-amidino-2-(2, 6-dichlorophenyl)acetamide hydrochloride (BS 100-141). Arzneimittelforschung 1975;25:1483-1491.
30. Ernsberger P, Giuliano R, Willette RN, Reis DJ. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990;253:408-418.
31. Ernsberger P, Giuliano R, Willette RN, Granata AR, Reis DJ. Hypotensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha-2-adrenergic receptors in the rostral ventrolateral medulla. J Hypertens Suppl 1988;6:S554-S557.
32. Meeley MP, Ernsberger P, McCauley PM, Reis DJ. Clonidine-specific antibodies as models for imidazole and alpha 2-adrenergic receptor binding sites: Implications for the structure of clonidine-displacing substance. J Hypertens Suppl 1988;6:S490-S493.
33. Head GA. Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents. Ann N Y Acad Sci 1999;881:279-286.
34. Trenk D, Wagner F, Jahnchen E, Planitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol 1987;27:988-993.
35. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl 1999;17:S29-S35.
36. Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Int J Clin Pract Suppl 2004;139:26-32.
37. Jacob S, Klimm HJ, Rett K, Helsberg K, Haring HU, Godicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004;112:315-322.
38. Bock C, Niederhoffer N, Szabo B. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine. Naunyn Schmiedebergs Arch Pharmacol 1999;359:262-271.
39. Hieble JP, Kolpak DC. Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors. Br J Pharmacol 1993;110:1635-1639.
40. Vayssettes-Courchay C, Bouysset F, Cordi AA, Laubie M, Verbeuren TJ. A comparative study of the reversal by different alpha 2-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine. Br J Pharmacol 1996;117:587-593.
41. Urban R, Szabo B, Starke K. Is the sympathoinhibitory effect of rilmenidine mediated by alpha-2 adrenoceptors or imidazoline receptorsJ Pharmacol Exp Ther 1994;270:572-578.
42. Urban R, Szabo B, Starke K. Involvement of alpha 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur J Pharmacol 1995;282:19-28.
43. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984;230:232-236.
44. Bousquet P. Imidazoline receptors: From basic concepts to recent developments. J Cardiovasc Pharmacol 1995;26(Suppl 2):S1-S6.
45. Raddatz R, Parini A, Lanier SM. Localization of the imidazoline binding domain on monoamine oxidase B. Mol Pharmacol 1997;52:549-553.
46. Brown CA, Chan SL, Stillings MR, Smith SA, Morgan NG. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080. Br J Pharmacol 1993;110:1017-1022.
47. Ferry D, Armah BI, Goll A, Glossmann H. Characteristics of the binding of the antihypertensive agent moxonidine to alpha 2-adrenoceptors in rat brain membranes. Arzneimittelforschung 1988;38:1442-1445.
48. Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P. The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. Eur J Pharmacol 1989;162:1-9.
49. Kamisaki Y, Ishikawa T, Takao Y, Omodani H, Kuno N, Itoh T. Binding of [3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: Distribution of imidazoline binding sites in rat brain. Brain Res 1990;514:15-21.
50. Ernsberger P, Meeley MP, Mann JJ, Reis DJ. Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 1987;134:1-13.
51. Garcia-Sevilla JA, Escriba PV, Guimon J. Imidazoline receptors and human brain disorders. Ann N Y Acad Sci 1999;881:392-409.
52. Piletz JE, Jones JC, Zhu H, Bishara O, Ernsberger P. Imidazoline receptor antisera-selected cDNA clone and mRNA distribution. Ann N Y Acad Sci 1999;881:1-7.
53. Ivanov TR, Jones JC, Dontenwill M, Bousquet P, Piletz JE. Characterization of a partial cDNA clone detected by imidazoline receptor-selective antisera. J Auton Nerv Syst 1998;72:98-110.
54. Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res 1998;780:270-293.
55. Piletz JE, Andrew M, Zhu H, Feng YZ, Rains J, Halaris A. Alpha 2-adrenoceptors and I1-imidazoline binding sites: Relationship with catecholamines in women of reproductive age. J Psychiatr Res 1998;32:55-64.
56. Piletz JE, Halaris A. Involvement of I1-imidazoline receptors in mood disorders. Ann N Y Acad Sci 1995;763:510-519.
57. Molderings GJ, Gothert M, Christen O, Schafer SG. Imidazole receptors and blood pressure regulation. High receptor selectivity of moxonidine. Dtsch Med Wochenschr 1993;118:953-958.
58. Steffen G, Dendorfer A, Dominiak P. Imidazoline binding sites on PC12 cells and bovine chromaffin cells. Ann N Y Acad Sci 1995;763:157-162.
59. Piletz JE, Sletten K. Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther 1993;267:1493-1502.
60. Atlas D, Burstein Y. Isolation and partial purification of a clonidine-displacing endogenous brain substance. Eur J Biochem 1984;144:287-293.
61. Atlas D, Burstein Y. Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS Lett 1984;170:387-390.
62. Reis DJ, Regunathan S. Agmatine: An endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst 1998;72:80-85.
63. Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brainTrends Pharmacol Sci 2000;21:187-193.
64. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: An endogenous clonidine-displacing substance in the brain. Science 1994;263:966-969.
65. Piletz JE, Chikkala DN, Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J Pharmacol Exp Ther 1995;272:581-587.
66. Pinthong D, Hussain JF, Kendall DA, Wilson VG. Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha 2-adrenoceptor binding sites. Br J Pharmacol 1995;115:689-695.
67. Pinthong D, Wright IK, Hanmer C, Millns P, Mason R, Kendall DA, Wilson VG. Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1995;351:10-16.
68. Musgrave IF, Badoer, E. Harmane produces hypotension following microinjection into the RVLM: Possible role of I-imidazoline receptors. Br J Pharmacol 2000;129:1057-1059.
69. Moncrieff J. Determination of pharmacological levels of harmane, harmine and harmaline in mammalian brain tissue, cerebrospinal fluid and plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 1989;496:269-278.
70. Anderson NJ, Tyacke RJ, Husbands SM, Nutt DJ, Hudson AL, Robinson ES. In vitro and ex vivo distribution of [3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology 2006;50:269-276.
71. Anderson NJ, Seif I, Nutt DJ, Hudson AL, Robinson ES. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J Neurochem 2006;96:1551-1559.
72. Prell GD, Martinelli GP, Holstein GR, et al. Imidazoleacetic acid-ribotide: An endogenous ligand that stimulates imidazol(in)e receptors. Proc Natl Acad Sci U S A 2004;101:13677-13682.
73. Parini A, Moudanos CG, Pizzinat N, Lanier SM. The elusive family of imidazoline binding sites. Trends Pharmacol Sci 1996;17:13-16.
74. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP. 'Seeing through a glass darkly': Casting light on imidazoline 'I' sites. Trends Pharmacol Sci 1998;19:381-390.
75. Raddatz R, Savic SL, Bakthavachalam V, et al. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J Pharmacol Exp Ther 2000;292:1135-1145.
76. Tyacke RJ, Robinson ES, Nutt DJ, Hudson AL. 5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline(2) binding site ligand: In vitro and in vivo characterisation in rat brain. Neuropharmacology 2002;43:75-83.
77. Diaz A, Mayet S, Dickenson AH. BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. Eur J Pharmacol 1997;333:9-15.
78. Rustenbeck I, Herrmann C, Ratzka P, Hasselblatt A. Imidazoline/guanidinium binding sites and their relation to inhibition of K(ATP) channels in pancreatic B-cells. Naunyn Schmiedebergs Arch Pharmacol 1997;356:410-417.
79. Proks P, Ashcroft FM. Phentolamine block of KATP channels is mediated by Kir6.2. Proc Natl Acad Sci U S A 1997;94:11716-11720.
80. Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA. Imidazolines and pancreatic hormone secretion. Ann N Y Acad Sci 1999;881:217-228.
81. Chan SL, Brown CA, Scarpello KE, Morgan NG. The imidazoline site involved in control of insulin secretion: Characteristics that distinguish it from I1- and I2-sites. Br J Pharmacol 1994;112:1065-1070.
82. Clews J, MN, Ramsden CA. Preparation of the I3 imidazoline receptor antagonist KU14R and related 2, 3-dihyrobenzo[b]furan derivatives. Synthesis 2001;10:1546-1550.
83. Squires PE, Hills CE, Rogers GJ, Garland P, Farley SR, Morgan NG. The putative imidazoline receptor agonist, harmane, promotes intracellular calcium mobilisation in pancreatic beta-cells. Eur J Pharmacol 2004;501:31-39.
84. Morgan NG, Cooper EJ, Squires PE, Hills CE, Parker CA, Hudson AL. Comparative effects of efaroxan and beta-carbolines on the secretory activity of rodent and human beta cells. Ann N Y Acad Sci 2003;1009:167-174.
85. Ernsberger P, Graves ME, Graff LM, et al. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci 1995;763:22-42.
86. Molderings GJ, Bonisch H, Hammermann R, Gothert M, Bruss M. Noradrenaline release-inhibiting receptors on PC12 cells devoid of alpha(2(-)) and CB(1) receptors: Similarities to presynaptic imidazoline and edg receptors. Neurochem Int 2002;40:157-167.
87. Guroff G. PC12 cells as a model of neuronal differentiation. In: Bottenstein JE, Sato G, editors. Cell culture in the neurosciences: ed1. New York, Plenum Press, 1985;245-272.
88. Regunathan S, Meeley MP, Reis DJ. Effect of clonidine on second messenger systems in rat adrenal gland. Life Sci 1990;47:2127-2133.
89. Regunathan S, Evinger MJ, Meeley MP, Reis DJ. Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells. Biochem Pharmacol 1991;42:2011-2018.
90. Liedtke CM, Furin J, Ernsberger P. Alpha 2-adrenergic, but not imidazole, agonists activate NaCl cotransport in rabbit tracheal epithelial cells. Am J Physiol 1993;264(3 Pt 1):C568-C576.
91. Greney H, Ronde P, Magnier C, et al. Coupling of I(1) imidazoline receptors to the cAMP pathway: Studies with a highly selective ligand, benazoline. Mol Pharmacol 2000;57:1142-1151.
92. Liedtke CM, Ernsberger P. Regulation of electrolyte transport in rabbit tracheal epithelial cells by the I1-imidazoline agonist moxonidine. Ann N Y Acad Sci 1995;763:401-404.
93. Separovic D, Kester M, Ernsberger P. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol Pharmacol 1996;49:668-675.
94. Ernsberger P. Arachidonic acid release from PC12 pheochromocytoma cells is regulated by I1-imidazoline receptors. J Auton Nerv Syst 1998;72:147-154.
95. Muller-Decker K. Interruption of TPA-induced signals by an antiviral and antitumoral xanthate compound: Inhibition of a phospholipase C-type reaction. Biochem Biophys Res Commun 1989;162:198-205.
96. Separovic D, Kester M, Haxhiu MA, Ernsberger P. Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res 1997;749:335-339.
97. Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M, Ernsberger P. The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J Neurochem 2001;79:931-940.
98. Piletz JE, Ivanov TR, Sharp JD, et al. Imidazoline receptor antisera-selected (IRAS) cDNA: Cloning and characterization. DNA Cell Biol 2000;19:319-329.
99. Alahari SK, Lee JW, Juliano RL. Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J Cell Biol 2000;151:1141-54.
100. Alahari SK, Reddig PJ, Juliano RL. The integrin-binding protein Nischarin regulates cell migration by inhibiting PAK. EMBO J 2004;23:2777-2788.
101. Dontenwill M, Piletz JE, Chen M, et al. IRAS is an anti-apoptotic protein. Ann N Y Acad Sci 2003;1009:400-412.
102. Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE. Insulin receptor substrate 4 associates with the protein IRAS. J Biol Chem 2002;277:19439-19447.
103. Gavras I, Manolis AJ, Gavras H. The alpha2 -adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens 2001;19:2115-2124.
104. Esler M. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: The transition from mechanisms to medical management. J Appl Physiol 2010;108:227-237.
105. Mobini R, Fu M, Jansson PA, Bergh CH, Scharin Tang M, Waagstein F, Andersson B. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: Acute effects of the imidazoline I1-receptor agonist moxonidine. Clin Sci (Lond) 2006;110:329-36.
106. Esler M, Kaye D. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J Auton Nerv Syst 1998;72:210-219.
107. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002;105:1797-1803.
108. Pocock S, Wilhelmsen L, Dickstein K, Francis G, Wittes J. The data monitoring experience in the MOXCON trial. Eur Heart J 2004;25:1974-198.
109. Ernsberger P, Ishizuka T, Liu S, Farrell CJ, Bedol D, Koletsky RJ, Friedman JE. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 1999;288:139-147.
110. Sun Z, Ernsberger P. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. J Pharmacol Exp Ther 2007;320:845-852.
111. Velliquette RA, Ernsberger P. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 2003;306:646-657.
112. Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol 2006;372:300-312.
113. Edwards L, Ernsberger P. Cross-Talk between I1-imidazoline and insulin receptor signaling: A mechanism for moxonidine's antidiabetic actionsJ. Hypertension 2000;18:S129.
114. Penicaud L, Berthault MF, Morin J, Dubar M, Ktorza A, Ferre P. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens Suppl 1998;16:S45-S49.
115. Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 2005;21:113-119.
116. Yakubu-Madus FE, Johnson WT, Zimmerman KM, Dananberg J, Steinberg MI. Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes 1999;48:1093-1100.
117. Lumb PJ, McMahon Z, Chik G, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract 2004;58:465-468.
118. Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: A comparison with metformin. Diabetes Obes Metab 2006;8:456-465.
119. Vengerovskii AI, Idrisova EM, Bushkova EA, Mananko EI, Krasnova NMThe influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome. Eksp Klin Farmakol 2008;71:8-12.
120. Topal E, Cikim AS, Cikim K, Temel I, Ozdemir R. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs 2006;6:343-348.
121. Poyhonen-Alho MK, Manhem K, Katzman P, et al. Central sympatholytic therapy has antiinflammatory properties in hypertensive postmenopausal women. J Hypertens 2008;26:2445-2449.
122. Ebinc H, Ozkurt ZN, Ebinc FA, Ucardag D, Caglayan O, Yilmaz M. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. J Int Med Res 2008;36:80-87.